Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece

The purpose of the present study is to estimate the impact of pharmaceutical spending reduction on public revenue, based on data from the national health accounts as well as on reports of Greece’s organizations. The methodology of the analysis is structured in two basic parts. The first part prese...

Full description

Bibliographic Details
Main Authors: Kyriakos eSouliotis, Manto ePapageorgiou, Anastasia ePoliti, Nikolaos eFrangos, Yiannis eTountas
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-08-01
Series:Frontiers in Public Health
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fpubh.2015.00203/full
_version_ 1818268252684419072
author Kyriakos eSouliotis
Manto ePapageorgiou
Anastasia ePoliti
Nikolaos eFrangos
Yiannis eTountas
author_facet Kyriakos eSouliotis
Manto ePapageorgiou
Anastasia ePoliti
Nikolaos eFrangos
Yiannis eTountas
author_sort Kyriakos eSouliotis
collection DOAJ
description The purpose of the present study is to estimate the impact of pharmaceutical spending reduction on public revenue, based on data from the national health accounts as well as on reports of Greece’s organizations. The methodology of the analysis is structured in two basic parts. The first part presents the urgency for rapid cutbacks on public pharmaceutical costs due to the financial crisis and provides a conceptual framework for the contribution of the Greek pharmaceutical branch to the country’s economy. In the second part, we perform a quantitative analysis for the estimation of multiplier effects of public pharmaceutical expenditure reduction on main revenue sources such as taxes and social contributions. We also fit projection models with multipliers as regressands for the evaluation of the efficiency of the particular fiscal measure in the short run. According to the results, near half of the gains from the measure’s application is offset by financially equivalent decreases in the government’s revenue, i.e. losses in tax revenues and social security contributions alone, not considering any other direct or indirect costs. The findings of multipliers’ high value and increasing short-term trend imply the measure’s inefficiency henceforward and signal the risk of vicious circles that will provoke the economy’s deprivation of useful resources.
first_indexed 2024-12-12T20:35:32Z
format Article
id doaj.art-bab03a3bea1b4d2893aa630332f96e56
institution Directory Open Access Journal
issn 2296-2565
language English
last_indexed 2024-12-12T20:35:32Z
publishDate 2015-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Public Health
spelling doaj.art-bab03a3bea1b4d2893aa630332f96e562022-12-22T00:12:55ZengFrontiers Media S.A.Frontiers in Public Health2296-25652015-08-01310.3389/fpubh.2015.00203148519Estimating the fiscal effects of public pharmaceutical expenditure reduction in GreeceKyriakos eSouliotis0Manto ePapageorgiou1Anastasia ePoliti2Nikolaos eFrangos3Yiannis eTountas4University of PeloponneseUniversity of PeloponneseAthens University of Economics and BusinessAthens University of Economics and BusinessNational and Kapodistrian University of AthensThe purpose of the present study is to estimate the impact of pharmaceutical spending reduction on public revenue, based on data from the national health accounts as well as on reports of Greece’s organizations. The methodology of the analysis is structured in two basic parts. The first part presents the urgency for rapid cutbacks on public pharmaceutical costs due to the financial crisis and provides a conceptual framework for the contribution of the Greek pharmaceutical branch to the country’s economy. In the second part, we perform a quantitative analysis for the estimation of multiplier effects of public pharmaceutical expenditure reduction on main revenue sources such as taxes and social contributions. We also fit projection models with multipliers as regressands for the evaluation of the efficiency of the particular fiscal measure in the short run. According to the results, near half of the gains from the measure’s application is offset by financially equivalent decreases in the government’s revenue, i.e. losses in tax revenues and social security contributions alone, not considering any other direct or indirect costs. The findings of multipliers’ high value and increasing short-term trend imply the measure’s inefficiency henceforward and signal the risk of vicious circles that will provoke the economy’s deprivation of useful resources.http://journal.frontiersin.org/Journal/10.3389/fpubh.2015.00203/fullGreeceUnemploymentMultipliersRevenueFiscal consolidationpublic pharmaceutical expenditure
spellingShingle Kyriakos eSouliotis
Manto ePapageorgiou
Anastasia ePoliti
Nikolaos eFrangos
Yiannis eTountas
Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
Frontiers in Public Health
Greece
Unemployment
Multipliers
Revenue
Fiscal consolidation
public pharmaceutical expenditure
title Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
title_full Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
title_fullStr Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
title_full_unstemmed Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
title_short Estimating the fiscal effects of public pharmaceutical expenditure reduction in Greece
title_sort estimating the fiscal effects of public pharmaceutical expenditure reduction in greece
topic Greece
Unemployment
Multipliers
Revenue
Fiscal consolidation
public pharmaceutical expenditure
url http://journal.frontiersin.org/Journal/10.3389/fpubh.2015.00203/full
work_keys_str_mv AT kyriakosesouliotis estimatingthefiscaleffectsofpublicpharmaceuticalexpenditurereductioningreece
AT mantoepapageorgiou estimatingthefiscaleffectsofpublicpharmaceuticalexpenditurereductioningreece
AT anastasiaepoliti estimatingthefiscaleffectsofpublicpharmaceuticalexpenditurereductioningreece
AT nikolaosefrangos estimatingthefiscaleffectsofpublicpharmaceuticalexpenditurereductioningreece
AT yiannisetountas estimatingthefiscaleffectsofpublicpharmaceuticalexpenditurereductioningreece